cariprazine (vraylar) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cariprazine is an antipsychotic approved by FDA for the treatment of schizophrenia and bipolar I disorder. The drug has a unique clinical action which is explained by its ability to act on dopamine D3 receptors. Pharmacology studies revealed that cariprazine is a dual partial agonist of dopamine D2 and D3 receptors as well as serotonin 5HT1a, 2a and 2b receptors.   NCATS

Chemistry

  • SMILES: CN(C)C(=O)N[C@@H]1CC[C@@H](CCN2CCN(CC2)c3cccc(Cl)c3Cl)CC1
  • InChIKey: KPWSJANDNDDRMB-QAQDUYKDSA-N
  • Mol. Mass: 427.42
  • ALogP: 4.34
  • ChEMBL Molecules:
    cariprazine  
    cariprazine hydrochloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$30.0015 - $40.5178
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cariprazine | cariprazine hcl | cariprazine hydrochloride | mp-214 | rgh-188 | rgh-188 hcl | trans-4-(2-(4-(2,3-dichlorophenyl)piperazine-1-yl)-ethyl)-n,n-dimethylcarbamoyl-cyclohexyl-amine hydrochloride | trans-n-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-n’,n’-dimethylurea hydrochloride | vraylar

Organizations (25)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (2)


 

Bipolar Disorder

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Anxiety Disorders (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Autism Spectrum Disorder (Phase 3)

Bipolar Disorder (Phase 4)

Cocaine-Related Disorders (Phase 2)

Cognitive Dysfunction (Phase 3)

Depression (Phase 3)

Depressive Disorder, Major (Phase 4)

Mania (Phase 3)

Opioid-Related Disorders (Phase 2)

Pharmacokinetics (Phase 1)

Phobia, Social (Phase 4)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 52
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue